Dose-Response Study of Norepinephrine Infusion for Maternal Hypotension in Preeclamptic Patients Undergoing Cesarean Delivery Under Spinal Anesthesia Yi ChenLei GuoXinli Ni Original Research Article 13 June 2024
Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug–Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective Hee Jae ChoiShilpa MadariFenglei Huang Current Opinion Open access 13 June 2024
Pharmacogenetic Testing or Therapeutic Drug Monitoring: A Quantitative Framework Maddalena CentanniNiels ReijnhoutLena E. Friberg Original Research Article Open access 06 June 2024
Development of a Physiologically Based Pharmacokinetic Population Model for Diabetic Patients and its Application to Understand Disease-drug–drug Interactions Yafen LiXiaonan LiDongyang Liu Original Research Article 31 May 2024
Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population Patricia D. MaglalangJaydeep Sinhathe Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee Original Research Article 30 May 2024
Together or Apart? Revealing the Impact of Dietary Interventions on Bioavailability of Quinolones: A Systematic Review with Meta-analyses Agnieszka WiesnerPaweł ZagrodzkiPaweł Paśko Systematic Review Open access 28 May 2024
Drugs in Human Milk Part 1: Practical and Analytical Considerations in Measuring Drugs and Metabolites in Human Milk Osama Y. AlshogranPrerna DodejaRaman Venkataramanan Review Article 15 May 2024 Pages: 561 - 588
Comment on: “CYP3A4*22 Genotype‑Guided Dosing of Kinase Inhibitors in Cancer Patients” Thijs H. Oude MunninkSaskia K. KleinDaan J. Touw Letter to the Editor 11 May 2024
The Effect of Various Degrees of Renal or Hepatic Impairment on the Pharmacokinetic Properties of Once-Weekly Insulin Icodec Hanne HaahrBlanka CieslarováStanislav Ignatenko Original Research Article Open access 09 May 2024
Population Pharmacokinetics of Intravenous Lidocaine in Adults: A Systematic Review Keng Wah FoongSook Hui ChawPui San Loh Systematic Review 04 May 2024 Pages: 623 - 643
Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers Lisanne A. H. BeversAnne E. M. KamphuisAngela Colbers Correction Open access 02 May 2024 Pages: 729 - 730
Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model Yulan QiMing Liang ChanJoshua Henshaw Original Research Article Open access 23 April 2024 Pages: 707 - 719
Time-Varying Clearance in Milrinone Pharmacokinetics from Premature Neonates to Adolescents Conor J. O’HanlonAnita SumpterJacqueline A. Hannam Original Research Article Open access 13 April 2024 Pages: 695 - 706
Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors Mei TangAmit GargSrinivasu Poondru Review Article Open access 12 April 2024 Pages: 423 - 438
Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review J. van GendtR. EmausPaola Mian Systematic Review Open access 07 April 2024 Pages: 589 - 622
Tacrolimus Variability and Clinical Outcomes in the Early Post-lung Transplantation Period: Oral Versus Continuous Intravenous Administration Julia E. M. van DommelenHeleen GrootjansMaaike A. Sikma Original Research Article Open access 06 April 2024 Pages: 683 - 693
Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors Abhishek G. SatheIndrajeet SinghAhmed A. Othman Original Research Article Open access 05 April 2024 Pages: 669 - 681
Comment on “Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies” and “High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints” Leping KongJan-Willem C. AlffenaarSophie L. Stocker Letter to the Editor 04 April 2024 Pages: 731 - 733
Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers Lisanne A. H. BeversAnne E. M. KamphuisAngela Colbers Original Research Article Open access 04 April 2024 Pages: 721 - 728
Have We Neglected to Study Target-Site Drug Exposure in Children? A Systematic Review of the Literature Eline HermansJozefien MeersschautPieter A. De Cock Systematic Review 29 March 2024 Pages: 439 - 468
Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling Krina MehtaPavel BalazkiJ. G. Coen van Hasselt Original Research Article Open access 26 March 2024 Pages: 657 - 668
Personalized Antifungal Therapy Through Model-Informed Precision Dosing of Posaconazole Anouk M. E. JansenKim SnijdelaarRob ter Heine Original Research Article Open access 26 March 2024 Pages: 645 - 656
Population Pharmacodynamic Dose–Response Analysis of Serum Potassium Following Dosing with Sodium Zirconium Cyclosilicate Robert C. PenlandMagnus ÅstrandMats Någård Original Research Article Open access 19 March 2024 Pages: 551 - 560
Optimization of Ganciclovir and Valganciclovir Starting Dose in Children by Machine Learning Laure PonthierJulie AutmizguineJean-Baptiste Woillard Original Research Article 16 March 2024 Pages: 539 - 550
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease Nanja C. BeversRon J. KeizerPatrick F. van Rheenen Original Research Article Open access 15 March 2024 Pages: 529 - 538
Clinical Pharmacokinetics and Pharmacodynamics of Naloxone Teijo I. SaariJohn StrangOla Dale Review Article Open access 14 March 2024 Pages: 397 - 422
Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy Yi MaZaiwei SongZhanmiao Yi Systematic Review 09 March 2024 Pages: 279 - 291
Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation Alex YuAnasuya HazraAlberto Russu Original Research Article Open access 04 March 2024 Pages: 511 - 527
Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study Sammy HuygensTim PreijersBart J. A. Rijnders Original Research Article Open access 01 March 2024 Pages: 497 - 509
Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration Joseph PiscitelliMicaela B. ReddyJason H. Williams Original Research Article Open access 29 February 2024 Pages: 483 - 496
Bayesian Vancomycin Model Selection for Therapeutic Drug Monitoring in Neonates Dua’a AlrahahlehYann ThomaJan-Willem Alffenaar Original Research Article Open access 28 February 2024 Pages: 367 - 380
A Population Pharmacokinetic Analysis of l-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects Alina SadafMin DongCharles T. Quinn Original Research Article Open access 24 February 2024 Pages: 357 - 365
Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers Brit S. RohrEvelyn KrohmerWalter E. Haefeli Original Research Article Open access 23 February 2024 Pages: 469 - 481
Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm Yeamin HuhJessica WojciechowskiVivek S. Purohit Original Research Article Open access 15 February 2024 Pages: 381 - 394
Towards More Robust Evaluation of the Predictive Performance of Physiologically Based Pharmacokinetic Models: Using Confidence Intervals to Support Use of Model-Informed Dosing in Clinical Care Marjolein D. van BorselenLaurens Auke Æmiel SluijtermanSaskia N. de Wildt Original Research Article Open access 15 February 2024 Pages: 343 - 355
Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy Naïm BouazzaSaïk UrienIsabelle Sermet-Gaudelus Original Research Article 04 February 2024 Pages: 333 - 342
Reporting Coefficient of Variation for Logit, Box-Cox and Other Non-log-normal Parameters John P. Prybylski Commentary 01 February 2024 Pages: 133 - 135
Salivary Therapeutic Drug Monitoring of Antimicrobial Therapy: Feasible or Futile? Lina Davies ForsmanHannah Yejin KimJan-Willem C. Alffenaar Current Opinion Open access 01 February 2024 Pages: 269 - 278
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis Jonathan GreenzaidSteven Feldman Review Article 27 January 2024 Pages: 137 - 153
Maternal Ezetimibe Concentrations Measured in Breast Milk and Its Use in Breastfeeding Infant Exposure Predictions Cindy H. T. YeungJulie AutmizguineAndrea N. Edginton Original Research Article 26 January 2024 Pages: 317 - 332
Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation Jingcheng ChenYuchen QuDongyang Liu Original Research Article 20 January 2024 Pages: 303 - 316
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer Yan JiHilmar SchillerAbhijit Chakraborty Review Article Open access 20 January 2024 Pages: 155 - 170
Comment on: Anti-Coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug–Drug Interactions Lorenz Van der LindenThomas VanasschePeter Verhamme Letter to the Editor 18 January 2024 Pages: 395 - 396
Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis Hongtao YuMagnus ÅstrandAnis A. Khan Original Research Article 18 January 2024 Pages: 255 - 267
Pharmacokinetics, Disposition, and Biotransformation of [14C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion Elijah WeberRaju SubramanianRenu Singh Original Research Article 18 January 2024 Pages: 241 - 253
Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study Yuru FanXuan ZhangWei Hu Original Research Article 10 January 2024 Pages: 293 - 302
Pharmacokinetics, Pharmacodynamics, and Safety of Single Dose HSK7653 Tablets in Chinese Subjects with Normal or Impaired Renal Function Dan ShiLin ChenDongliang Zhang Original Research Article 06 January 2024 Pages: 227 - 239
Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action K. P. van RheeC. A. J. KnibbeR. J. M. Brüggemann Current Opinion Open access 05 January 2024 Pages: 1 - 12
A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir Jacqueline GerhartDonna S. CoxBharat Damle Review Article Open access 04 January 2024 Pages: 27 - 42
Factors Influencing Unfractionated Heparin Pharmacokinetics and Pharmacodynamics During a Cardiopulmonary Bypass Audrick GibertJulien LanoiseléeEdouard Ollier Original Research Article 02 January 2024 Pages: 211 - 225